Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 2.74
SUPN's Cash to Debt is ranked higher than
76% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.43 vs. SUPN: 2.74 )
SUPN' s 10-Year Cash to Debt Range
Min: 0.19   Max: No Debt
Current: 2.74

Equity to Asset 0.52
SUPN's Equity to Asset is ranked higher than
63% of the 810 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. SUPN: 0.52 )
SUPN' s 10-Year Equity to Asset Range
Min: -2.25   Max: 0.61
Current: 0.52

-2.25
0.61
F-Score: 4
Z-Score: 3.37
M-Score: 29.20
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) 8.02
SUPN's Operating margin (%) is ranked higher than
73% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.41 vs. SUPN: 8.02 )
SUPN' s 10-Year Operating margin (%) Range
Min: -37851.89   Max: 27.1
Current: 8.02

-37851.89
27.1
Net-margin (%) -6.78
SUPN's Net-margin (%) is ranked higher than
57% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.06 vs. SUPN: -6.78 )
SUPN' s 10-Year Net-margin (%) Range
Min: -36285.85   Max: 6701.74
Current: -6.78

-36285.85
6701.74
ROE (%) -19.75
SUPN's ROE (%) is ranked higher than
56% of the 876 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.84 vs. SUPN: -19.75 )
SUPN' s 10-Year ROE (%) Range
Min: -202.72   Max: -138.13
Current: -19.75

-202.72
-138.13
ROA (%) -6.23
SUPN's ROA (%) is ranked higher than
58% of the 909 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.17 vs. SUPN: -6.23 )
SUPN' s 10-Year ROA (%) Range
Min: -90.03   Max: 106.84
Current: -6.23

-90.03
106.84
ROC (Joel Greenblatt) (%) 153.23
SUPN's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 904 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.06 vs. SUPN: 153.23 )
SUPN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3115.47   Max: 1356
Current: 153.23

-3115.47
1356
Revenue Growth (3Y)(%) 75.70
SUPN's Revenue Growth (3Y)(%) is ranked higher than
99% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.40 vs. SUPN: 75.70 )
SUPN' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 75.7
Current: 75.7

0
75.7
EBITDA Growth (3Y)(%) -52.20
SUPN's EBITDA Growth (3Y)(%) is ranked higher than
50% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.50 vs. SUPN: -52.20 )
SUPN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: -52.2
Current: -52.2

EPS Growth (3Y)(%) -52.30
SUPN's EPS Growth (3Y)(%) is ranked higher than
53% of the 658 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. SUPN: -52.30 )
SUPN' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: -52.3
Current: -52.3

» SUPN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

SUPN Guru Trades in

SUPN Guru Trades in

Q2 2014

SUPN Guru Trades in Q2 2014

Robert Bruce 100,000 sh (New)
Louis Moore Bacon 100,000 sh (New)
» More
Q3 2014

SUPN Guru Trades in Q3 2014

Jim Simons 36,700 sh (New)
Robert Bruce 400,000 sh (+300%)
Louis Moore Bacon Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SUPN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Robert Bruce 2014-09-30 Add 300%0.73%$7.99 - $11.13 $ 8.48-6%400000
Robert Bruce 2014-06-30 New Buy0.25%$7.32 - $10.85 $ 8.48-4%100000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.50
SUPN's P/B is ranked higher than
63% of the 959 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. SUPN: 5.50 )
SUPN' s 10-Year P/B Range
Min: 3.23   Max: 18.63
Current: 5.5

3.23
18.63
P/S 3.90
SUPN's P/S is ranked higher than
74% of the 959 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.02 vs. SUPN: 3.90 )
SUPN' s 10-Year P/S Range
Min: 3.34   Max: 157
Current: 3.9

3.34
157
EV-to-EBIT 39.90
SUPN's EV-to-EBIT is ranked higher than
75% of the 959 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.35 vs. SUPN: 39.90 )
SUPN' s 10-Year EV-to-EBIT Range
Min: -11.8   Max: 50.8
Current: 39.9

-11.8
50.8
Current Ratio 4.65
SUPN's Current Ratio is ranked higher than
84% of the 881 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.41 vs. SUPN: 4.65 )
SUPN' s 10-Year Current Ratio Range
Min: 1.51   Max: 7.26
Current: 4.65

1.51
7.26
Quick Ratio 4.15
SUPN's Quick Ratio is ranked higher than
85% of the 881 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. SUPN: 4.15 )
SUPN' s 10-Year Quick Ratio Range
Min: 1.51   Max: 7.26
Current: 4.15

1.51
7.26
Days Inventory 667.54
SUPN's Days Inventory is ranked higher than
55% of the 959 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 149.40 vs. SUPN: 667.54 )
SUPN' s 10-Year Days Inventory Range
Min: 1372.72   Max: 1372.72
Current: 667.54

Days Sales Outstanding 54.99
SUPN's Days Sales Outstanding is ranked higher than
85% of the 959 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 86.21 vs. SUPN: 54.99 )
SUPN' s 10-Year Days Sales Outstanding Range
Min: 2.71   Max: 16387.12
Current: 54.99

2.71
16387.12

Valuation & Return

vs
industry
vs
history
Price/Net Cash 29.25
SUPN's Price/Net Cash is ranked higher than
87% of the 959 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. SUPN: 29.25 )
SUPN' s 10-Year Price/Net Cash Range
Min: 4.22   Max: 62.83
Current: 29.25

4.22
62.83
Price/Net Current Asset Value 12.29
SUPN's Price/Net Current Asset Value is ranked higher than
86% of the 959 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. SUPN: 12.29 )
SUPN' s 10-Year Price/Net Current Asset Value Range
Min: 4.17   Max: 223.5
Current: 12.29

4.17
223.5
Price/Tangible Book 5.88
SUPN's Price/Tangible Book is ranked higher than
69% of the 959 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.66 vs. SUPN: 5.88 )
SUPN' s 10-Year Price/Tangible Book Range
Min: 3.85   Max: 19.29
Current: 5.88

3.85
19.29
Price/Median PS Value 0.09
SUPN's Price/Median PS Value is ranked higher than
100% of the 959 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.29 vs. SUPN: 0.09 )
SUPN' s 10-Year Price/Median PS Value Range
Min: 0.09   Max: 2.95
Current: 0.09

0.09
2.95
Earnings Yield (Greenblatt) 2.40
SUPN's Earnings Yield (Greenblatt) is ranked higher than
74% of the 904 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. SUPN: 2.40 )
SUPN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2   Max: 2.4
Current: 2.4

2
2.4

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:S49.Germany,
Supernus Pharmaceuticals Inc., was incorporated in Delaware on March 30, 2005. It is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company markets two epilepsy products, Oxtellar XR and Trokendi XR, and has several proprietary product candidates in clinical development that address the attention deficit hyperactivity disorder market. The Company has a broad portfolio of drug development technologies consisting of six platforms that include the following: Microtrol, Solutrol (matrix delivery platform) and EnSoTrol. In addition to Oxtellar XR and Trokendi XR, the Company's proprietary technologies have been used in the following approved products: Carbatrol, Adderall XR, and Intuniv, marketed by Shire; Equetro, marketed by Validus Pharmaceuticals Inc.; Sanctura XR, marketed by Allergan, Inc.; Oracea, marketed by Galderma Laboratories, L.P.; and Orenitram. Oxtellar XR and Trokendi XR are novel extended release formulations of two well known and approved AEDs, oxcarbazepine and topiramate. The Company's psychiatry portfolio includes three product candidates for the treatment of impulsive aggression in patients with ADHD, ADHD or its coexisting conditions and one product candidate for depression, each of which is designed to bring important advancements in therapy. In addition to regulations in the United States, the Company will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of the product candidates to the extent company choose to clinically evaluate or sell any products outside of the United States.
» More Articles for SUPN

Headlines

Articles On GuruFocus.com
Third Quarter Was Robert Bruce's Busiest in 2014 Nov 21 2014 
Supernus Pharmaceuticals Reports Insider Buys Mar 26 2013 


More From Other Websites
Nasdaq stocks posting largest percentage increases Jan 26 2015
Supernus Files Oxtellar XR Patent Infringement Lawsuit Again - Analyst Blog Jan 26 2015
SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 23 2015
Supernus Sues TWi for Infringement of Oxtellar XR(R) Patents Jan 21 2015
Supernus Sues TWi for Infringement of Oxtellar XR(R) Patents Jan 21 2015
Supernus Downgraded as Lead Drugs Face Patent Challenges - Analyst Blog Jan 20 2015
Supernus Sues Par for Infringement of Trokendi XR(R) Patents Jan 16 2015
Supernus Sues Par for Infringement of Trokendi XR(R) Patents Jan 16 2015
SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events Jan 13 2015
Why Supernus Pharmaceuticals (SUPN) Might Be a Diamond in the Rough Dec 15 2014
SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 11 2014
Supernus Faces another Patent Challenge for Oxtellar XR Dec 11 2014
Supernus Faces New Patent Challenge for Trokendi XR Dec 10 2014
Supernus Announces Paragraph IV ANDA Filing for Oxtellar XR(R) Dec 10 2014
Supernus Announces Paragraph IV ANDA Filing for Oxtellar XR(R) Dec 10 2014
Supernus Announces Paragraph IV ANDA Filing for Trokendi XR(R) Dec 09 2014
Supernus Announces Paragraph IV ANDA Filing for Trokendi XR(R) Dec 09 2014
Why Supernus Pharmaceuticals (SUPN) Could Be Positioned for a Surge? Dec 02 2014
How Supernus Pharmaceuticals (SUPN) Stock Stands Out in a Strong Industry Dec 01 2014
SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Nov 25 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK